SG Americas Securities
CGTX icon

SG Americas Securities’s Cognition Therapeutics CGTX Stock Holding History

SG Americas Securities’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,107
Closed -$10K – 3018
2025
Q1 		$10K Sell
23,107
-14,001
-38% -$8.23K ﹤0.01% 3409
2024
Q4 		$26K Buy
+37,108
New +$18.3K ﹤0.01% 2986

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

SG Americas Securities's CGTX Position: Q2 2025 in Review

SG Americas Securities sold out of Cognition Therapeutics (CGTX) in Q2 2025, closing a stake of 23,107 shares — an estimated $10K sold.

SG Americas Securities first reported a position in CGTX in Q4 2024 and held it in 2 quarters. The position peaked at $26K in Q4 2024. 48 funds tracked by Wall St. Rank hold CGTX as of Q2 2025.

  • SG Americas Securities reported no remaining Cognition Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 23,107 Cognition Therapeutics shares in Q2 2025, an estimated $10K.
  • SG Americas Securities first reported a position in Cognition Therapeutics in Q4 2024 and held it in 2 quarters.
  • SG Americas Securities's Cognition Therapeutics position peaked at $26K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.